Abstract 873P
Background
PIK3CA mutations led to the activation of PI3K-AKT-mTOR signaling pathway. This pathway controls cell proliferation, growth, differentiation, migration, and apoptosis. In clinical practice, only a minority of patients with HNSC derive benefit from immunotherapy and the need for the discovery of novel biomarkers to optimize treatment strategies is becoming increasingly more relevant. Whether mutations of PIK3CA are associated with clinical efficacy of immunotherapy (ICIs) in HNSC have not been reported.
Methods
We used cBioportal to collected clinical and mutation data of the MSKCC cohort including 139 patients receiving ICIs. Gene expression data and WES mutation data of 502 samples in the TCGA were obtained for further analysis of the potential biological mechanisms between PIK3CA-MT and PIK3CA-WT tumors. TMB was calculated as the total number of somatic non-synonymous mutations per megabase in both MSKCC and TCGA cohorts. CIBERSORT algorithm was applied to infer 22 human immune cell type proportions in TCGA HNSC.
Results
The TMB level of PIK3CA-Mut patients was higher than PIK3CA-WT patients in both MSKCC (Median [IQR]: 7.02[4.92-10.53] vs. 4.91[2.63-7.90], P=0.006) and TCGA (Median [IQR]: 3.03[1.98-4.42] vs. 2.62[1.66-3.92], P=0.045) cohort. In MSKCC cohort, compared to PIK3CA-WT patients, the PIK3CA-Mut patients achieved prolonged OS (median OS: 25.0 vs. 9.0 months, HR (95%CI): 0.51(0.27-0.94), P=0.029). Moreover, a multivariable analysis across the MSKCC cohort using Cox proportional-hazards regression demonstrated that PIK3CA-Mut was associated with better OS (HR= 0.49; 95%CI, 0.26-0.91; P=0.025), after adjusting for age, gender, metastasis and treatment. Then we used CIBERSORT to explore infiltration of immune cells and two types of immune cells (CD8+ T-cells, CD4+ naïve T-cells) were higher expression in PIK3CA-Mut tumors (P<0.05). These results indicated PIK3CA-Mut tumors had an activated antitumor immune microenvironment.
Conclusions
PIK3CA-Mut is associated with higher TMB in ICI-treated HNSC patients. Survival analysis shows PIK3CA-Mut have a good link with longer OS after immunotherapy. These findings indicate that PIK3CA mutation may serve as a potential predictive biomarker for ICIs in HNSC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
910P - Machine learning-based survival prediction model for postoperative parotid mucoepidermoid carcinoma
Presenter: Chen Zihan
Session: Poster session 12
911P - Post-radiotherapy (RT) Epstein-Barr virus (EBV) DNA dynamics identifies optimal timepoint for stratification of high-risk nasopharyngeal carcinoma (NPC)
Presenter: Janice Ser Huey Tan
Session: Poster session 12
912P - Toripalimab in combination with anlotinib in previously treated recurrent or metastatic nasopharyngeal carcinoma: The interim analysis of the single-arm, phase II TORAL study
Presenter: QingQing Cai
Session: Poster session 12
916P - Reducing radiation-induced temporal lobe injury by changing tumor prescription dose in nasopharyngeal carcinoma
Presenter: Xiao Xiao
Session: Poster session 12
917P - Radiation-induced nasopharyngeal necrosis in locally-recurrent nasopharyngeal carcinoma patients after re-radiotherapy
Presenter: Runda Huang
Session: Poster session 12
918P - SPP1-related M2 macrophage signatures predict prognosis and immunotherapy response in patients with nasopharyngeal carcinoma
Presenter: Li Ying
Session: Poster session 12
919P - A prognostic model of nasopharyngeal carcinoma based on 18F-FDG PET-CT radiomic parameters and clinical characteristics of patients
Presenter: Wu xi
Session: Poster session 12
920P - Envafolimab plus chemoradiotherapy for locally advanced nasopharyngeal carcinoma (NPC), a prospective, single-armed phase II trial
Presenter: Xiaohui Wang
Session: Poster session 12
921P - HB-200 arenavirus-based immunotherapy plus pembrolizumab as a first-line treatment of patients with recurrent/metastatic HPV16 positive head and neck cancer
Presenter: Lisle Nabell
Session: Poster session 12